Jonah F Byrne, Colm Healy, Melanie Föcking, Meike Heurich, Subash Raj Susai, David Mongan, Kieran Wynne, Eleftheria Kodosaki, Scott W Woods, Barbara A Cornblatt, William S Stone, Daniel H Mathalon, Carrie E Bearden, Kristin S Cadenhead, Jean Addington, Elaine F Walker, Tyrone D Cannon, Mary Cannon, Clark Jeffries, Diana Perkins, David R Cotter
INTRODUCTION: Negative symptoms impact the quality of life of individuals with psychosis and current treatment options for negative symptoms have limited effectiveness. Previous studies have demonstrated that complement and coagulation pathway protein levels are related to later psychotic experiences, psychotic disorder, and functioning. However, the prognostic relationship between complement and coagulation proteins and negative symptoms is poorly characterised. METHODS: In the North American Prodrome Longitudinal Studies 2 and 3, negative symptoms in 431 individuals at clinical high-risk for psychosis (mean age: 18...
March 29, 2024: Brain, Behavior, and Immunity